

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Expert Committee on Biological Standardization

Twenty-eighth Report

World Health Organization
Technical Report Series
610



World Health Organization Geneva 1977

ISBN 92 4 120610 1

© World Health Organization 1977

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

CONTENTS

	Page
General	7
SUBSTANCES	
Blood Products and Related Substances	
1. Blood Typing Sera	10
2. Anti-(A+B), Anti-C and Anti-E Blood Typing Sera.	10
3. Anti-c Incomplete Blood Typing Serum	11
4. Anti-D Immunoglobulin.	11
5. Anti-Hepatitis B Immunoglobulin	12
6. Anti-Varicella Zoster Immunoglobulin	12
7. Blood Coagulation Factor VIII.	12
8. Blood Coagulation Factor IX	13
9. Plasmin	13
10. Thromboplastins	14
11. Ancrod	15
12. Fluorescein Isothiocyanate-Conjugated Sheep Anti-Human Immuno- globulin	15
Antibiotics	
13. Candicidin.	16
14. Bleomycin and Doxorubicin	16
15. Spectinomycin	16
16. Tobramycin	17
17. Ristocetins.	17
Antigens	
18. Diphtheria Toxoid, Adsorbed	17
19. Tetanus Toxoid, Adsorbed.	17
20. Tetanus Toxin	18
21. Carcinoembryonic Antigen.	18
22. Purified Protein Derivative of Bovine Tuberculin (for Veterinary Use)	18
Antitoxins	
23. <i>Clostridium botulinum</i> Type B Antitoxin	19
Reagents	
24. Adenovirus Antisera Types 4, 19, 20, 22, 23 and 24.	19

REQUIREMENTS FOR BIOLOGICAL SUBSTANCES

25. Requirements for Red Blood Cells for Immunization	20
26. Requirements for the Processing and Control of Human Blood and its Derivatives	20
27. Requirements for Meningococcal Polysaccharide Vaccine	20
28. Requirements for Rubella Vaccine (Live)	21
29. Requirements for <i>Brucella melitensis</i> Strain Rev. 1 Vaccine (Live — for Veterinary Use)	21
30. Requirements for Antibiotic Susceptibility Discs	22

MISCELLANEOUS

31. List of Biological Substances	23
---	----

ANNEXES

Annex 1. Report of a WHO Working Group on the Standardization of Human Blood Products and Related Substances	24
Appendix 1 — List of participants	43
Appendix 2 — Standardization in the control of anticoagulation (oral)	45
Annex 2. Requirements for Meningococcal Polysaccharide Vaccine (Addendum 1976).	52
Annex 3. Requirements for Rubella Vaccine (Live)	54
Appendix — Summary protocol of rubella vaccine production . . .	80
Annex 4. Requirements for <i>Brucella melitensis</i> Strain Rev. 1 Vaccine (Live — for Veterinary Use).	85
Annex 5. Requirements for Antibiotic Susceptibility Tests	
I. Agar Diffusion Tests using Antibiotic Susceptibility Discs . . .	98
Appendix 1 — Calculation of content from assay data	125
Appendix 2 — Criteria for interpretation based on the Bauer Kirby procedure	127
Annex 6. Requirements for biological substances and other sets of recommendations	129
Annex 7. Biological substances: international standards, reference preparations, and reference reagents	132

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 16–22 November 1976

Members *

Dr Chou Hai-chun, Deputy Director of the Revolutionary Committee of the Peking Institute for the Control of Pharmaceutical and Biological Products, Peking, China

Professor S. G. Dzagurov, Director, Tarasevič State Institute for the Standardization and Control of Medical Biological Preparations, Moscow, USSR

Dr Sutas Guptarak, Deputy Director-General, Department of Medical Sciences, Bangkok, Thailand

Professor Susan R. Hollán, Director, National Institute of Haematology and Blood Transfusion, Budapest, Hungary (*Vice-Chairman*)

Dr J. W. Lightbown, Head, Division of Antibiotics, National Institute for Biological Standards and Control, London, England

Dr H. Mirchamsy, Associate Director, Razi State Institute of Serum and Vaccine Production, Teheran, Iran

Dr J. Spaun, Director, Department of Biological Standardization, State Serum Institute, Copenhagen, Denmark

Mr J. R. Thayer, Chief Inspector, National Biological Standards Laboratory, Canberra, A.C.T., Australia (*Chairman*)

Dr D. P. Thomas, Head, Division of Blood Products, National Institute for Biological Standards and Control, London, England (*Rapporteur*)

Dr W. W. Wright, Deputy Associate Director, Pharmaceutical Research and Testing, Bureau of Drugs, Food and Drug Administration, Washington, DC, USA

Representative of the Food and Agriculture Organization

Dr Y. Ozawa, Animal Health Officer (Infectious Diseases), Animal Production and Health Division, Food and Agriculture Organization, Rome, Italy

Secretariat

Dr D. R. Bangham, Head, Division of Hormones, National Institute for Biological Standards and Control, London, England (*Consultant*)

Professor A. Eyquem, Chief, Immunohaematology and Immunopathology Service, Director of the Blood Transfusion Centre, Pasteur Institute, Paris, France (*Consultant*)

Dr F. T. Perkins, Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)

* Unable to attend : Professor Y. Chabbert, Chief, Unit for Studies on Sensitivity to Antibiotics, Assistant Director, Pasteur Institute, Paris, France ; Dr P. Tuchinda, Under-Secretary of State for Public Health, Ministry of Public Health, Bangkok, Thailand.

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Twenty-eighth Report

The WHO Expert Committee on Biological Standardization met in Geneva from 16 to 22 November 1976. The meeting was opened on behalf of the Director-General by Dr Ch'en Wen-chieh, Assistant Director-General, who observed that much of the agenda of the meeting would be concerned with human blood components and derivatives. A WHO Working Group on the Standardization of Human Blood Products and Related Substances had met in Geneva from 5 to 10 July 1976, and the report of the Group was to be considered in detail as it contained a number of important recommendations. In addition to the establishment of a number of standards and reference preparations, a particular recommendation was the need for the formulation of requirements for the manufacture and control of blood products.

Antibiotics, said Dr Ch'en, were also to be considered and the requirements for antibiotic susceptibility discs would fulfil an urgent need. The increase in antibiotic resistance of organisms was causing concern in many countries and it was essential to be able to compare these findings between countries. The List of Biological Substances had been brought up to date and the substances listed alphabetically within each category in order to facilitate reference. Reference reagents had been reintroduced into the list because of many inquiries concerning the availability of those preparations.

GENERAL

The Committee noted the report of the WHO Working Group on the Standardization of Human Blood Products and Related Substances and considered that the treatment of one particular field in depth by a group of specialists in this manner had been most productive. When necessary, problems in other fields could with advantage be approached in a similar way. The Committee agreed that the report of the Working Group should be annexed to this report (Annex 1).

The use of international units to specify the potency of blood typing sera should be strongly encouraged since international standards have now been established for the four blood typing sera of the greatest practical importance—namely, those for A, B, D and c antigens. The use of the international units will lead to more accurate quantification in the control of potency of blood typing sera, and the use of titres—the traditional way of describing the strength of these sera—should be discouraged. The prophylaxis, monitoring, and treatment of haemolytic disease of the newborn has concentrated particular effort on the quantification of anti-D antibodies. The use of automated instruments for measuring the potency of sera has extended the working dilution range several hundredfold and, as a result, numerical values of endpoint “titres” are cumbersome. The production of sera is now more extensive than ever before, and standardization for their control (for potency, specificity, and stability) is necessary.

The Committee recalled the resolutions of the World Health Assembly that countries should adopt international units to express the potency of biological materials.¹ It is important that this be done widely and rapidly following the establishment of international standards. In those instances where national units differ from the international units the repercussions could be hazardous in clinical practice and cause difficulties in the international exchange of materials and information. It is important, therefore, that national authorities inform WHO of any decision not to use established international units and report the reasons for the decision.

The Fisher-Race nomenclature for Rh blood typing is becoming more widely accepted, and the Committee agreed that it should be universally adopted in the interests of simplicity and uniformity (Annex 1, Part B, section 1). The Committee was informed that studies were in progress to determine whether this system could conveniently be used with computers.

With regard to the collaboration of international scientific organizations with the Expert Committee on Biological Standardization (Annex 1, Part C), the Committee agreed that contact with such specialist organizations could facilitate the rapid dissemination and implementation of WHO recommendations on biological standardization. It could also ensure the availability of specialized help with particular problems and with the establishment of international reference materials. To avoid

¹ See, for example, WHO Handbook of Resolutions and Decisions, Volume II, first edition, 1975, p. 16 (Resolution WHA26.32).

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30842

